Jim Simons Revance Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$56.7 Billion
Q2 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 572,000 shares of RVNC stock, worth $1.47 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

572,000

Previous 373,700 53.06%

Holding current value

$1.47 Million

Previous $1.84 Million 20.07%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$2.34 - $4.73 $464,022 - $937,959	198,300 Added 53.06%	572,000 $1.47 Million
Q1 2024 May 13, 2024	BUY	$4.65 - $9.31 $1.74 Million - $3.48 Million	373,700 New	373,700 $1.84 Million
Q3 2023 Nov 14, 2023	SELL	$11.47 - $25.07 $367,234 - $802,666	-32,017 Reduced 15.21%	178,500 $2.05 Million
Q2 2023 Aug 11, 2023	BUY	$24.7 - $37.61 $5.2 Million - $7.92 Million	210,517 New	210,517 $5.33 Million
Q2 2020 Aug 13, 2020	SELL	$12.6 - $26.55 $5.96 Million - $12.6 Million	-472,700 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$12.46 - $27.81 $2.55 Million - $5.69 Million	-204,773 Reduced 30.23%	472,700 $7 Million
Q4 2019 Feb 13, 2020	SELL	$11.66 - $20.15 $2.32 Million - $4.01 Million	-198,900 Reduced 22.7%	677,473 $11 Million
Q3 2019 Nov 13, 2019	SELL	$10.22 - $14.5 $4.65 Million - $6.59 Million	-454,600 Reduced 34.16%	876,373 $11.4 Million
Q2 2019 Aug 12, 2019	BUY	$10.67 - $15.49 $4.58 Million - $6.64 Million	428,900 Added 47.55%	1,330,973 $17.3 Million
Q1 2019 May 14, 2019	BUY	$15.4 - $20.39 $5.09 Million - $6.73 Million	330,200 Added 57.74%	902,073 $14.2 Million
Q4 2018 Feb 13, 2019	BUY	$18.06 - $24.96 $10.3 Million - $14.3 Million	571,873 New	571,873 $11.5 Million

Others Institutions Holding RVNC

# of Institutions

196

Shares Held

81.5M

Call Options Held

490K

Put Options Held

128K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account